



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000003039 M 12/05/1988 31 Y

Referral Testing

Collected: 07/13/2020 09:08

Received: 07/13/2020 09:08

Test Name	Result	Flag	Ref-Ranges	Units	Site
-----------	--------	------	------------	-------	------

MGMT Promoter Methylation Dection

Block ID	TEST9876				ARRL
----------	----------	--	--	--	------

Performed By: ARUP Laboratories
500 Chipeta Way
Salt Lake City, UT 84108

Laboratory Director: Julio C. Delgado, MD, MS

MGMT Promoter Methylation Dection Result	Detected	AB			ARRL
--	----------	----	--	--	------

MGMT promoter methylation was detected.

This result has been reviewed and approved by Georgios Deftereos, M.D.

INTERPRETIVE INFORMATION: MGMT Promoter Methylation
Detection

CHARACTERISTICS: This assay is designed to detect MGMT promoter methylation. MGMT promoter methylation status is a prognostic biomarker in patients with high grade gliomas and is useful in treatment decisions. For specific treatment recommendations please refer to NCCN Clinical Practice Guidelines in Oncology for Central Nervous System Cancers (www.nccn.org).

METHODOLOGY: Genomic DNA is isolated from microscopically-guided dissection of tumor tissue. Bisulfite conversion and subsequent polymerase chain reaction (PCR) amplification of region of interest is followed by enzymatic cleavage at thymine residues. The resulting fragments, which differ in molecular mass based on CpG site methylation status, are analyzed by MassARRAY matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry to determine CpG methylation status. Methylation status of MGMT promoter CpG sites 72-83 and 86-89 is evaluated. Total methylation is calculated as an average across listed CpG sites. Total methylation of 0-9 percent is reported as "Not detected" 10-29 percent as "Low level" and equal or more than 30 percent as "Detected".

LIMITATIONS: Methylation at locations other than those listed above will not be detected.

ANALYTICAL SENSITIVITY: 5 percent methylation.

CLINICAL DISCLAIMER: Results of this test must always be

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

B513000004
WX0000003039
Printed D&T: 07/13/20 09:11

Ordered By: CLIENT CLIENT
WX00000000001595

William G. Finn, M.D. - Medical Director
Form: MM RL1
PAGE 1 OF 2



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000003039 M 12/05/1988 31 Y

Referral Testing

Collected: 07/13/2020 09:08

Received: 07/13/2020 09:08

<u>Test Name</u>	<u>Result</u>	<u>Flag</u>	<u>Ref-Ranges</u>	<u>Units</u>	<u>Site</u>
------------------	---------------	-------------	-------------------	--------------	-------------

interpreted within the clinical context and other relevant data and should not be used alone for a diagnosis of malignancy.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

Performing Site:

ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

B513000004
WX0000003039

Printed D&T: 07/13/20 09:11

Ordered By: CLIENT CLIENT
WX00000000001595

William G. Finn, M.D. - Medical Director

Form: MM RL1

PAGE 2 OF 2